open access
Progress in adjuvant treatment of melanoma patients
open access
Abstract
Surgery is therapy of choice in melanoma patients. However, prognosis of patients at stage IIC–IV even after radical resection is very heterogenous and related to high risk of disease relapse. Positive results of clinical trials indicate that in the nearest future systemic adjuvant therapy in high risk melanomas will become the standard of care. New treatment modalities, both molecular targeted therapy with BRAF+MEK inhibitors dabrafenib with trametinib and immunotherapy anti-PD-1 with nivolumab or pembrolizumab have been approved in US and EU.
Abstract
Surgery is therapy of choice in melanoma patients. However, prognosis of patients at stage IIC–IV even after radical resection is very heterogenous and related to high risk of disease relapse. Positive results of clinical trials indicate that in the nearest future systemic adjuvant therapy in high risk melanomas will become the standard of care. New treatment modalities, both molecular targeted therapy with BRAF+MEK inhibitors dabrafenib with trametinib and immunotherapy anti-PD-1 with nivolumab or pembrolizumab have been approved in US and EU.
Keywords
melanoma, adjuvant therapy, BRAF, MEK inhibitors, immunotherapy, anti-PD-1
About this articleTitle
Progress in adjuvant treatment of melanoma patients
Journal
Nowotwory. Journal of Oncology
Issue
Article type
Review paper
Pages
140-145
Published online
2018-11-26
Page views
1004
Article views/downloads
975
DOI
Bibliographic record
Nowotwory. Journal of Oncology 2018;68(3):140-145.
Keywords
melanoma
adjuvant therapy
BRAF
MEK inhibitors
immunotherapy
anti-PD-1
Authors
Piotr Rutkowski
Wojciech M. Wysocki
Tomasz Świtaj
Arkadiusz Jeziorski